In this guide
What is Indole-3-Carbinol (I3C)?
Indole-3-carbinol forms when glucobrassicin in cruciferous vegetables is broken down. In acidic stomach conditions it converts into multiple condensation products, including DIM. Food exposure, an I3C capsule and a DIM product are therefore not interchangeable. [1], [4]
Typical Indole-3-Carbinol (I3C) Protocols
| Source and question | Preparation | Amount each administration | Daily total | Frequency and duration | Main interpretation |
|---|---|---|---|---|---|
| Reed 2005 · phase I · 17 high-risk women | Oral I3C after a 4-week placebo run-in | Administration count not reported in abstract | 400 mg/day for 4 weeks, then 800 mg/day for 4 weeks | Daily for each 4-week period | No significant serum-hormone change; CYP1A2 increased in 94%, averaging 4.1-fold at 800 mg/day |
| Bell 2000 · CIN II–III RCT · 30 randomized | Oral I3C versus placebo | Administration count not reported | 200 or 400 mg/day | Daily for 12 weeks | Complete regression in 4/8 and 4/9 versus 0/10 placebo; very small trial and not a replacement for treatment |
| Wong 1997 · biomarker trial · 60 enrolled | Oral I3C versus placebo | One capsule daily; amount depended on group | 50, 100, 200, 300 or 400 mg/day | Once daily for 4 weeks | Urinary estrogen-metabolite ratio changed at higher doses; surrogate endpoint, not cancer incidence |
| Rosen 2004 · open-label RRP follow-up | Oral I3C after complete surgical removal | 200 mg | 400 mg/day in adults | Twice daily; mean follow-up 4.8 years | 11/33 had remission and 10/33 reduced growth; no randomized comparator and surgery remained part of care |
- Exact product
- Record species, form, lot and co-ingredients.
- Each administration
- Keep amount, timing and context.
- Real endpoint
- Separate biomarker, symptom and clinical outcome.
What is it commonly used for?
Human studies have focused on estrogen-metabolite biomarkers and narrow clinical conditions. In 17 high-risk women, 400 then 800 mg/day changed CYP1A2 activity but did not significantly change measured serum hormones. A small cervical intraepithelial neoplasia trial reported lesion regression at 200 and 400 mg/day, while a dose-ranging study used a urinary estrogen-metabolite ratio as a surrogate. An open-label respiratory-papillomatosis series combined I3C with surgery. None establishes self-treatment of cancer or precancer. [1], [2], [4]
One result answers one question
How do forms and labels differ?
I3C, DIM, crucifer extracts and foods produce different exposures. Stomach chemistry, formulation and co-ingredients affect the products formed after swallowing. Record the exact compound, each administration, daily total, meal timing and interacting medicines rather than converting an I3C amount into a DIM amount. [4], [5]
How should the product be stored?
Follow the finished product’s label, keep it dry in its original container and away from children. Discard an expired, heat-damaged, broken-seal or untraceable product.
What does human research show?
| Question | Best direct evidence | Finding | Boundary |
|---|---|---|---|
| Efficacy | Reed 2005 · phase I · 17 high-risk women | No significant serum-hormone change; CYP1A2 increased in 94%, averaging 4.1-fold at 800 mg/day | Specific product and population |
| Replication | Limited evidence | No universal effect established | Variable formulations |
| Universal dose? | None | Not established | Rows cannot be combined |
Keep the finished product reviewable
What are the risks and interactions?
The clearest human interaction signal is induction of CYP1A2 activity, which can change exposure to medicines using that pathway. Hormone-active conditions, pregnancy, breastfeeding, liver disease, cancer treatment and drugs with narrow therapeutic ranges require pharmacist or clinician review. I3C must not delay evaluation or treatment of cervical, breast, airway or other lesions. [2], [3], [5], [6]
Seek prompt care for jaundice, severe abdominal symptoms, severe allergy, unexplained bleeding, airway or swallowing symptoms, or any worsening lesion under evaluation.
What is the legal and regulatory status?
In the United States, it is sold as a dietary supplement; FDA does not approve it for safety and effectiveness before sale. In Canada, verify the exact product, NPN and authorized label. Legal sale does not prove efficacy or sport suitability. [6]
When should use stop?
Stop for any allergic reaction, persistent symptom worsening, unexpected laboratory result or doubt about product identity.
What should be monitored?
Track product identity, I3C rather than DIM, each amount, daily total, medicines, caffeine response and adverse effects. For a clinical lesion, pathology and clinician-defined follow-up are the endpoints; a urinary estrogen ratio or enzyme probe cannot substitute for disease assessment.
What can community experience add?
Reports can describe odor, gastrointestinal tolerance and perceived cycle changes. They cannot establish CYP exposure, hormone safety or lesion regression. No systematic current community sample was assembled, so no detox or estrogen-balancing protocol is reported.
How do related options compare?
| Option | Main distinction |
|---|---|
| I3C capsule | Unstable precursor forming several acid-condensation products |
| DIM product | Different finished compound and evidence base |
| Cruciferous vegetables | Food matrix with variable glucosinolate exposure |
Common questions
Does I3C balance estrogen?
That broad claim is not established; one phase I study found no significant serum-hormone change.
What changed in that study?
CYP1A2 activity increased in most participants, creating an interaction concern.
Does the cervical trial prove treatment?
No. It was very small and cannot replace pathology-guided clinical care.
Is DIM the same dose?
No. I3C changes into several products and cannot be converted into a DIM dose.
Do urinary estrogen ratios prove prevention?
No. They are surrogate biomarkers, not cancer outcomes.
What should be tracked?
Exact compound, amount per dose, daily total, medicines and clinician-defined endpoint.
Glossary
Terms for reading the evidence.
- Endpoint
- A defined result measured in a study.
- Anaphylaxis
- A potentially life-threatening systemic allergic reaction.
- Biomarker
- A biological measure that does not guarantee clinical benefit.
- Standardization
- A measured specification for a product component.
- Cross-reactivity
- Immune recognition of related proteins from different sources.
How this guide was researched
NCBI identities, publication notices, indexed abstracts and available open methods were checked. Null outcomes, mixed products, surrogate endpoints and missing details remain visible.
Research record · checked October 9, 2026
Identity: NCBI EFetch verified every indexed source by exact title, first author, journal, pages and DOI; no descendant correction, retraction or expression of concern appeared.
Access: exact schedules were limited to indexed abstracts where full text was unavailable. Unreported administration counts were not inferred.
Boundary: biomarker changes, a small cervical trial and an open-label surgical cohort do not establish prevention or self-treatment.
Explore the sources
Primary human evidence and official context.
Showing 6 sources
- 01
A phase I study of indole-3-carbinol in women: tolerability and effects. ↗
Phase I human study
Seventeen women received 400 then 800 mg/day; serum hormones were unchanged while CYP1A2 activity increased markedly.
- 02
Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. ↗
Randomized controlled trial
Thirty patients with biopsy-proven CIN II–III were randomized to placebo, 200 or 400 mg/day for 12 weeks; the study was very small.
- 03
Dose-ranging study of indole-3-carbinol for breast cancer prevention. ↗
Randomized biomarker study
Sixty women enrolled for four weeks; higher doses changed a urinary estrogen-metabolite ratio, a surrogate rather than a cancer outcome.
- 04
Indole-3-carbinol for recurrent respiratory papillomatosis: long-term results. ↗
Prospective open-label study
Adults used 200 mg twice daily after surgery; 33 had long-term follow-up without a randomized comparator.
- 05
Indole-3-Carbinol and Its Metabolite DIM ↗
Institutional evidence overview
Separates preliminary human findings, CYP interactions and the absence of proof for cancer prevention or treatment.
- 06
FDA 101: Dietary Supplements ↗
Official supplement overview
FDA does not approve dietary supplements for safety and effectiveness before sale.
No matching sources
Try a different term or show the full list.
Editorial note
This guide separates composition, biomarker, symptom and clinical outcome. It does not turn a narrow signal into a general promise.